Drug Profile
D-aspartic-beta-hydroxamate
Alternative Names: DAHLatest Information Update: 28 Nov 2007
Price :
$50
*
At a glance
- Originator INSERM
- Class Antivirals
- Mechanism of Action Ribonucleoside diphosphate reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections